HMGN2P13: A Drug Target / Disease Biomarker (G100289682)

Target Name: HMGN2P13

NCBI ID: G100289682

HMGN2P13

Other Name(s): High mobility group nucleosomal binding domain 2 pseudogene 13 | high mobility group nucleosomal binding domain 2 pseudogene 13

HMGN2P13: A Drug Target / Disease Biomarker

HMGN2P13 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 13 and has been shown to play a role in the development and progression of various diseases.

One of the most promising aspects of HMGN2P13 is its potential as a drug target. The gene has been shown to be highly expressed in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, studies have shown that targeting the HMGN2P13 gene has the potential to inhibit the growth and spread of cancer cells.

Another potential use of HMGN2P13 as a drug target is its role as a biomarker. The gene has been shown to be expressed in a variety of tissues and fluids, including blood, saliva, and urine. This makes it a potential source of diagnostic information for cancer and other diseases. Additionally, the gene has been shown to be expressed in the urine of patients with various types of cancer, which could be used as a biomarker for monitoring disease progression and responding to treatment.

In addition to its potential as a drug target and biomarker, HMGN2P13 is also of interest to researchers because of its unique genetic structure. The gene is located on chromosome 13, which is known as the X chromosome. This makes it unique because most genes on the X chromosome are located in the nucleus, while HMGN2P13 is located in the cytoplasm. This is of interest because it suggests that the gene may have a different mechanism of action than other genes on the X chromosome.

Overall, HMGN2P13 is a promising gene for the development of new drugs or as a biomarker for the treatment of various diseases. Further research is needed to fully understand its potential as a drug target and biomarker.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 13

The "HMGN2P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets